Israeli researchers have pioneered the Liquid Biopsy

Israeli Technological progress has brought about many changes in the field of medicine. Methods that in the past were considered science fiction, are now used as an alternative to diagnose diseases without invading the patient's body. For example, the use of robotic surgery was previously considered impossible, but today it is a standard practice in hospitals.  This time, a non-invasive way to detect prostate cancer is shaking up the medical community, with some calling the 'liquid biopsy' a game changer in the early diagnosis of cancer.

Similarly, the development of artificial organs and prostheses has revolutionized the way we treat patients. These are just two examples of how science fiction has become a reality in the field of medicine. As for cancer, in the past biopsy was the most common method for diagnosing prostate cancer, however, traditional biopsies that require taking a sample from the organ where the tumor is located are an invasive procedure.

Liquid biopsy is a non-invasive diagnostic technique that involves the analysis of various biomarkers present in body fluids such as blood, urine, and saliva. This technique, which is performed from a simple blood sample, is easy and fast for the patient and has gained significant attention in Israel in recent years due to its potential to detect cancer at an early stage, monitor the progress of the disease and predict the response to treatment.

This technique is less invasive than traditional biopsy methods, which require the removal of tissue samples from the body. Liquid biopsy is already revolutionizing the diagnosis and treatment of cancer, and ongoing studies are examining its use in other diseases as well. While blood tests may not completely replace biopsies in all cases, they offer a promising alternative that can save patients time, discomfort, and risk.

In recent months, a non-invasive method for diagnosing prostate cancer entered Israel as part of the advanced category of liquid biopsy. This is a new blood test that makes it possible to detect aggressive prostate cancer with an impressive accuracy rate of about 90%. The revolutionary aspect of the test called IsoPSA lies in the decoding technology, which identifies changes in the structure of the protein extracted from the blood sample that result solely from the development of a cancerous tumor.

As a result, doctors can more reliably determine how likely a patient is to have significant prostate cancer. The test was originally developed as a diagnostic tool developed by researchers at the Cleveland Clinic in the United States but is being heavily invested in by Israeli medical researchers. One of the main advantages of the test is its ability to reduce the number of unnecessary biopsies. Because by using it, doctors can identify which patients have a high risk of prostate cancer and only refer them to a biopsy, and which patients can completely avoid the need for this invasive operation. The test was recently approved by the Israeli Ministry of Health and has already revolutionized the field of prostate cancer diagnosis in Israel.

Sign Up For The Judean Newsletter

I agree with the Terms and conditions and the Privacy policy